These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

239 related articles for article (PubMed ID: 30032336)

  • 1. Congenital Myasthenic Syndromes: a Clinical and Treatment Approach.
    Farmakidis C; Pasnoor M; Barohn RJ; Dimachkie MM
    Curr Treat Options Neurol; 2018 Jul; 20(9):36. PubMed ID: 30032336
    [TBL] [Abstract][Full Text] [Related]  

  • 2. β2-Adrenergic receptor agonists ameliorate the adverse effect of long-term pyridostigmine on neuromuscular junction structure.
    Vanhaesebrouck AE; Webster R; Maxwell S; Rodriguez Cruz PM; Cossins J; Wickens J; Liu WW; Cetin H; Cheung J; Ramjattan H; Palace J; Beeson D
    Brain; 2019 Dec; 142(12):3713-3727. PubMed ID: 31633155
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Therapeutic strategies for congenital myasthenic syndromes.
    Lee M; Beeson D; Palace J
    Ann N Y Acad Sci; 2018 Jan; 1412(1):129-136. PubMed ID: 29381222
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Congenital myasthenic syndromes: phenotypic expression and pathophysiological characterisation].
    Andreux F; Hantaï D; Eymard B
    Rev Neurol (Paris); 2004 Feb; 160(2):163-76. PubMed ID: 15034473
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Genetic, serological and clinical evaluation of childhood myasthenia syndromes- single center subgroup analysis experience in Turkey.
    Özsoy Ö; Cinleti T; Günay Ç; Sarıkaya Uzan G; Giray Bozkaya Ö; Çağlayan AO; Hız Kurul S; Yiş U
    Acta Neurol Belg; 2023 Dec; 123(6):2325-2335. PubMed ID: 37656362
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Congenital myasthenic syndromes.
    Hantaï D; Richard P; Koenig J; Eymard B
    Curr Opin Neurol; 2004 Oct; 17(5):539-51. PubMed ID: 15367858
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Congenital myasthenic syndromes: pathogenesis, diagnosis, and treatment.
    Engel AG; Shen XM; Selcen D; Sine SM
    Lancet Neurol; 2015 Apr; 14(4):420-34. PubMed ID: 25792100
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Congenital myasthenic syndromes.
    Harper CM
    Semin Neurol; 2004 Mar; 24(1):111-23. PubMed ID: 15229798
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Myasthenia gravis and myasthenic syndromes.
    Engel AG
    Ann Neurol; 1984 Nov; 16(5):519-34. PubMed ID: 6095730
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Congenital myasthenic syndromes: difficulties in the diagnosis, course and prognosis, and therapy--The French National Congenital Myasthenic Syndrome Network experience].
    Eymard B; Stojkovic T; Sternberg D; Richard P; Nicole S; Fournier E; Béhin A; Laforêt P; Servais L; Romero N; Fardeau M; Hantaï D;
    Rev Neurol (Paris); 2013 Feb; 169 Suppl 1():S45-55. PubMed ID: 23452772
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Guideline for the management of myasthenic syndromes.
    Wiendl H; Abicht A; Chan A; Della Marina A; Hagenacker T; Hekmat K; Hoffmann S; Hoffmann HS; Jander S; Keller C; Marx A; Melms A; Melzer N; Müller-Felber W; Pawlitzki M; Rückert JC; Schneider-Gold C; Schoser B; Schreiner B; Schroeter M; Schubert B; Sieb JP; Zimprich F; Meisel A
    Ther Adv Neurol Disord; 2023; 16():17562864231213240. PubMed ID: 38152089
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Molecular bases and therapeutic strategies in defective neuromuscular transmissions: lessons learned from a prototypical synapse].
    Ohno K; Ito M; Masuda A
    Nihon Shinkei Seishin Yakurigaku Zasshi; 2009 Aug; 29(4):145-51. PubMed ID: 19764481
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Congenital myasthenic syndrome: a brief review.
    Lorenzoni PJ; Scola RH; Kay CS; Werneck LC
    Pediatr Neurol; 2012 Mar; 46(3):141-8. PubMed ID: 22353287
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Morphologic and immunopathologic findings in myasthenia gravis and in congenital myasthenic syndromes.
    Engel AG
    J Neurol Neurosurg Psychiatry; 1980 Jul; 43(7):577-89. PubMed ID: 6249893
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Treatment of slow-channel congenital myasthenic syndrome in a Thai family with fluoxetine.
    Dejthevaporn C; Wetchaphanphesat S; Pulkes T; Rattanasiri S; Engel AG; Witoonpanich R
    J Clin Neurosci; 2022 Feb; 96():85-89. PubMed ID: 34999496
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Congenital myasthenic syndromes].
    Ohno K
    Rinsho Shinkeigaku; 2012; 52(11):1159-61. PubMed ID: 23196549
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Treatment approach to congenital myasthenic syndrome in a patient with acetylcholine receptor deficiency].
    Ishigaki K; Murakami T; Ito Y; Yanagisawa A; Kodaira K; Shishikura K; Suzuki H; Hirayama Y; Osawa M
    No To Hattatsu; 2009 Jan; 41(1):37-42. PubMed ID: 19172815
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effective Treatment With Albuterol in DOK7 Congenital Myasthenic Syndrome in Children.
    Tsao CY
    Pediatr Neurol; 2016 Jan; 54():85-7. PubMed ID: 26552645
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Clinical and neurophysiological response to ephedrine in a patient affected with slow-channel congenital myasthenic syndrome.
    Eirís-Puñal J; Fuentes-Pita P; Gómez-Lado C; Pérez-Gay L; López-Vázquez A; Quintas-Rey R; Barros-Angueira F; Pardo J
    Rev Neurol; 2020 Sep; 71(6):221-224. PubMed ID: 32895905
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The therapy of congenital myasthenic syndromes.
    Engel AG
    Neurotherapeutics; 2007 Apr; 4(2):252-7. PubMed ID: 17395135
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.